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Background: Using microarray profiling of airway epithelial cells, we previously identified a Th2-high molecular
phenotype of asthma based on expression of periostin, CLCA1 and serpinB2 and characterized by specific
inflammatory, remodeling, and treatment response features. The goal of the current study was to develop a
qPCR-based assay of Th2 inflammation to overcome the limitations of microarray-based methods.
Methods: Airway epithelial brushings were obtained by bronchoscopy from two clinical studies comprising 44
healthy controls and 62 subjects with asthma, 39 of whom were studied before and after a standardized 8 week
course of inhaled corticosteroids (ICS). The qPCR-based expression of periostin, CLCA1 and serpinB2 were combined
into a single metric.
Results: In asthma, the three-gene-mean of periostin, CLCA1 and serpinB2 correlated with FeNO (r = 0.75,
p = 0.0002), blood eosinophils (r = 0.58, p = 0.003) and PC20 methacholine (r = -0.65, p = 0.0006), but not total serum
IgE (r = 0.33, p = 0.1). Higher baseline three-gene-mean correlated with greater improvement in FEV1 with ICS at 2,
4 and 8 weeks (all p < 0.05). By ROC analysis, the area under the curve (AUC) of the three-gene-mean for FEV1
improvement with ICS at 4 and 8 weeks was 0.94 and 0.87, respectively, which are higher than the AUCs of FeNO,
blood eosinophils, IgE or PC20. Th2 airway inflammation as measured by this three-gene-mean also had predictive
capacity for an improvement in symptoms.
Conclusions: The three-gene-mean of periostin, CLCA1 and serpinB2 in airway epithelial brushings identifies
Th2-high and low populations, is correlated with other Th2 biomarkers, and performs well for prediction of FEV1
improvement with ICS. The three-gene-mean provides a measurement of Th2 airway inflammation that is clinically
relevant and that can serve as a valuable tool to evaluate non-invasive biomarkers to predict treatment responses
to existing and emerging asthma therapies.
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Asthma is heterogeneous, and more refined phenotypic
subgroupings will be required to better guide clinical
management [1]. For example, serum IgE levels are used
to successfully target the anti-IgE monoclonal antibody
omalizumab [2], and sputum eosinophils have been used
to target the anti-IL5 antibody mepolizumab [3-5].
Nonetheless, most asthma guidelines do not account for* Correspondence: nirav.bhakta@ucsf.edu
1Cardiovascular Research Institute, University of California, San Francisco, USA
2Department of Medicine, Division of Pulmonary, Critical Care, Sleep and
Allergy, University of California, Room HSE-1355A, 513 Parnassus Avenue, Box
0130, San Francisco, CA 94143, USA
Full list of author information is available at the end of the article
© 2013 Bhakta et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orunderlying biological mechanisms in the decision to
treat with the most commonly used anti-inflammatory
therapy, inhaled corticosteroids (ICS). Indeed, random-
ized controlled trials have shown that 30-45% of patients
with asthma fail to have an improvement in FEV1 even
to high dose ICS [6,7], and 25% are not well-controlled
based upon symptoms [8]. These data suggest that bio-
markers are needed to determine who will benefit from
ICS or from progressive increases in ICS dosing. Fur-
thermore, as targeted therapies such as anti-IgE and
anti-interleukin-13 become more widely available, the
identification of the patients who are most likely to re-
spond will be critical.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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gene expression markers of a Th2-high molecular
phenotype of asthma [9]. In a clinical trial of ICS, only
this Th2-high subgroup had the expected increase in
FEV1. However, one practical limitation is that Th2 sta-
tus was established through unsupervised hierarchical
clustering of microarray data [9]. Disadvantages inherent
to clustering of microarray data include instability in
phenotype assignment, cost, inefficient use of RNA, and
only a dichotomous high vs low output. These limita-
tions have been partially addressed by the development
of a quantitative gene expression signature from airway
biopsies, but this metric still was constrained by the use
of microarray data [10]. Another limitation of our prior
work is that we did not concurrently measure the frac-
tion of exhaled nitric oxide (FeNO), an alternative bio-
marker of Th2 inflammation. Our overarching goal in
the current study was to develop a continuous metric of
Th2 inflammation based on qPCR that avoids the limita-
tions of array- and cluster-based phenotyping and that
can be used to standardize the measurement of Th2 in-
flammation across bronchoscopy-based asthma studies.
Our specific goals were to determine the relationship be-
tween our qPCR-based Th2 metric and other accepted
markers of Th2 inflammation including FeNO, and as-
certain how well this metric predicts lung function and




We studied two cohorts that were recruited sequentially
at UCSF. Our primary analyses were performed on the
more recent cohort (hereafter referred to as the primary
cohort) which has not previously been studied by mRNA
microarray or qPCR for Th2 phenotyping (miRNA data
are published elsewhere [11]). Additional analyses were
performed in a secondary cohort in which we have pre-
viously performed microarray-based Th2-phenotyping
[9]. See Additional file 1: Figure S1 for additional details
on these cohorts. The primary cohort comprised adults
aged 18-70 years recruited via community-based adver-
tising into two groups: 1) 22 healthy controls and 2) 32
subjects with mild-to-moderate asthma not on ICS.
Healthy controls had no history of asthma or allergic
rhinitis. Subjects with asthma had a participant-reported
history of asthma. Subjects with asthma were also
required to not have used inhaled or oral steroids for at
least 6 weeks prior to enrollment, to have airway
hyper-responsiveness (AHR) to methacholine (PC20 to
methacholine < = 8.0 mg/mL), and at least one of the
following: asthma symptoms on at least two days per
week, beta agonist use on at least two days per week, or
FEV1 < 85% of predicted. All participants were non-smokers defined as never smoker or former smokers with
no smoking for at least 1 year and total pack-years < = 15.
Additional exclusion criteria were pregnancy, upper re-
spiratory tract infection in the 4 weeks prior to enroll-
ment, and the use of certain other medications [11].
Brief description of the secondary cohort
In this report, the secondary cohort contributes 25
healthy controls and 38 subjects with mild asthma pre-
ICS, of which 18 received 8 weeks of ICS. The research
protocol is similar to that for the primary cohort [9],
with the following relevant differences: 1) FeNO and
symptoms were not measured; 2) ICS treatment was
with fluticasone 500 μg inhaled twice daily; 3) a second
bronchoscopy was performed at the end of 1 week after
the initiation of ICS, rather than at the end of 8 weeks
as in the primary cohort.
Research protocol in the primary cohort
Baseline characterization included detailed medical his-
tory and examination, spirometry, PC20 to methacholine
(highest concentration used: 10 mg/ml), measurement of
FeNO (NIOX MINO, Aerocrine), complete blood count
and differential and measurement of serum total IgE. On
the second study visit (1-2 weeks following the baseline
visit) subjects underwent bronchoscopy and subjects
with asthma were then treated with inhaled budesonide
180 μg twice daily for 8 weeks; subjects maintained diar-
ies of symptoms (shortness of breath, chest tightness,
wheeze, cough, or sputum) and returned for spirometry
at 2, 4 and 8 weeks. At 8 weeks, subjects underwent re-
peat bronchoscopy and blood draw for IgE and eosino-
phil measurements. All clinical studies were approved by
the University of California at San Francisco Committee
on Human Research, written informed consent was
obtained from all subjects, and all studies were
performed in accordance with the principles expressed
in the Declaration of Helsinki. The study was registered
at Clinicaltrials.gov (NCT00595153).
PCR
RNA extraction and two-step, nested-primer qPCR was
performed as previously described [12]. Epithelial brus-
hings obtained during research bronchoscopy were stored
in RLT, with subsequent RNA extraction using column-
based purification (Rneasy Micro, Qiagen). RNA quantity
was determined by a Nanodrop spectrophotometer
(Thermo). RNA quality was assessed on an Agilent
Bioanalyzer. 20 ng of RNA was reverse transcribed with
random hexamer primers (Superscript/VILO, Invitrogen),
and then amplified in multiplex for POSTN, CLCA1,
SERPINB2, and endogenous control genes (EEF1A1,
PPIA, RPL13A, DNAJA1, and ACTB in the primary
cohort; EEF1A1, PPIA, RPL13A in the secondary cohort)
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file 1: Table S1) and the Advantage polymerase and
reaction mix (Clontech). The resulting amplified cDNA
underwent uniplex qPCR with custom primers and
Taqman-based probes (BiosearchTechnologies; Additional
file 1: Table S1), with samples run across separate batches
(on a 7900 or Viia 7 from ABI). Potential batch effects
were corrected by adjusting cycle threshold (Ct) values on
a per-gene basis using samples that were replicated across
all three batches, using methods described previously [13].
For each gene, log2-transformed, normalized, relative ex-
pression values were generated by subtracting the Ct value
for a particular sample from the mean Ct of the control
genes (only EEF1A1, PPIA, RPL13A were used for com-
parability of qPCR data between the primary and second-
ary cohorts) for that sample. This approach assumes equal
PCR efficiency for all genes of 100%, and produces a result
that is mathematically equivalent to normalization of ex-
pression values by the geometric mean expression of the
control genes [14]. Relative, normalized, transcript quan-
tities were log2-transformed and then centered and scaled.
The Th2 metric is the mean of the centered and scaled
values for periostin, serpinB2, and CLCA1 and is labeled
the “three-gene-mean”.
Statistical methods
Statistical analyses were performed in R version 2.15.1
[15]. Correlations used Pearson's sample correlationTable 1 Baseline subject characteristics
Healthy control
Sample size of qPCR data 19
Age, years 34 ± 9
BMI 26 ± 4







FEV1, % predicted 99 ± 13
Δ FEV1 with albuterol (% of baseline) 5.0 ± .4.5
FEV1/FVC 0.78 ± 0.066
Methacholine PC20 (mg/ml) > 10 (n = 18)
IgE, IU/ml 20 (4–357), (n = 18
Blood eosinophils, ×109/L 0.11 (0.04-0.30)
FeNO 16 (9–49)
Values reported as mean ± standard deviation, or median (range). All data are from
(immediately before initiation of ICS). p- values are based on t-test or chi-square tes
* In cases of multiple ethnicities, the lowest-numbered ethnicity from this list is rep
6. White.coefficient. Univariate tests used a Welch's t test (for un-
equal variances) unless otherwise noted. Total serum
IgE, blood eosinophil concentrations, FeNO, and PC20
to methacholine were log-transformed prior to analysis.
ROC curves were computed using the pROC package
[16]. All plots were created with the ggplot2 package
[17]. p < 0.05 was taken as statistically significant, with-
out corrections for multiple testing.
Results
Study subjects in the primary cohort
Of 22 eligible healthy controls and 32 eligible subjects
with asthma, 20 and 26, respectively, underwent bron-
choscopy; 23 subjects with asthma underwent repeat
bronchoscopy at the end of 8 weeks. Data in this report
are from the 19 healthy controls, 24 subjects with
asthma pre-ICS, and 21 subjects post-ICS from whom
epithelial brushings and qPCR data were obtained
(Table 1). FEV1 and the ratio of FEV1 to FVC were lower
in subjects with asthma compared to healthy controls
but both groups had FEV1 > 80% predicted (Table 1).
Subjects with asthma had increases in multiple markers
of inflammation and atopy: FeNO, total serum IgE, and
blood eosinophils.
qPCR assay to determine the degree of Th2 inflammation
In our prior study, Th2-high vs low phenotype was
assigned through hierarchical clustering which separateds Asthmatics p value
24
33 ± 12 0.71







84 ± 13 0.0008
14.4 ± 9.5 0.0001
0.73 ± 0.074 0.02
0.57 (0.07-4.40) <0.0001
) 232 (2–6556) <0.0001
0.33 (0.05-0.75) <0.0001
62 (9–144), (n = 18) 0.0004
the baseline visit except spirometry, which are reported from visit 2
t for proportions unless otherwise noted.
orted: 1. Hispanic, 2. Black, 3. Pacific Islander, 4. Native American, 5. Asian,
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three epithelial-derived markers of Th2-driven inflam-
mation: CLCA1, periostin, and serpinB2 [9]. In the
current study, we developed a PCR-based assay for the
same three genes in epithelial brushings. The expression
levels of these three genes were intercorrelated across
healthy subjects and subjects with asthma (Additional
file 1: Figure S2). Given our aim to create an accurate
measure of the degree of Th2-driven inflammation
present in the airway, this intercorrelation suggested that
the effect of variation in individual genes (e.g. changes
not in response to Th2 cytokines) would be mitigated by
combining their expression values into a single metric.
Thus, the expression values for these three genes were
averaged into a single quantitative metric we call the
“three-gene-mean”, as described in the Methods. The
distribution of the three-gene-mean for subjects with
asthma not on ICS across both primary and secondary
cohorts has two peaks suggesting a natural separation
between subjects with low and high levels of Th2 inflam-
mation (Figure 1); nonetheless, it is clear there are a
considerable number of subjects with asthma with inter-
mediate levels of Th2 inflammation as well. The peak
corresponding to lower values is slightly shifted to the
right of the healthy distribution, indicating that as a
group, even asthmatic airways with low Th2 inflamma-
tion have more Th2 activity than healthy airways. In sub-













Figure 1 Distribution of airway epithelial metric of Th2
inflammation: three-gene-mean values. Smoothed distributions
of three-gene-mean values across both the primary study (n = 19
healthy controls, 24 subjects with asthma not on ICS, and 21
subjects with asthma subsequently treated with ICS—budesonide
180 μg twice daily for 8 weeks) and secondary study (n = 25 healthy
controls, 38 subjects with asthma not on ICS, and 18 subjects with
asthma subsequently treated with ICS—fluticasone 500 μg twice
daily for 8 weeks).reduction of Th2 airway inflammation towards healthy
values as measured by this metric (Figure 1).
Relationship of three-gene-mean to FeNO and other Th2-
markers
The three-gene-mean correlates extremely well with
FeNO both in the absence of ICS (r = 0.75, p = 0.0002),
and in the presence of ICS (r = 0.53, p = 0.024)
(Figure 2A). The three-gene-mean is also significantly
correlated with blood eosinophils in subjects with
asthma not using ICS (r = 0.58, p = 0.003) but this rela-
tionship is not significant in subjects on ICS (r = 0.40,
p = 0.07) (Figure 2B). Whether on or off ICS, the rela-
tionship between Th2 airway inflammation and total
serum IgE was not significant (r = 0.33, p = 0.1 off ICS;
r = 0.42, p = 0.07 on ICS; Figure 2C).
Relationship of three-gene-mean to airway hyper-
responsiveness
We found a highly significant correlation between the
three-gene-mean and PC20 methacholine measured at
baseline off ICS, with 43% of the variance in PC20
explained by the degree of Th2 inflammation (r = -0.65,
p = 0.0006; Figure 2D). This suggests that in people with
asthma, the degree of Th2 inflammation is a significant
determinant of AHR, the functional abnormality of air-
way smooth muscle which is characteristic of asthma.
Relationship of three-gene-mean to lung function
improvement with ICS
Higher baseline three-gene-mean was associated with
greater improvement in lung function with ICS treat-
ment at 2 weeks (r = 0.68, p = 0.0004), 4 weeks (r = 0.79,
p = 7×10-6) and 8 weeks (r = 0.47, p = 0.03) (Figure 3A).
In further analyses, we dichotomized Th2 status at 2
standard deviations above the mean of the healthy distri-
bution for three-gene-mean (Th2-high defined as > 0.1).
The mean percent change in FEV1 from baseline was
significantly higher in Th2-high compared to Th2-low
asthma at 2 weeks (difference of 9%, p = 0.004), 4 weeks
(difference of 12%, p = 0.0002) and 8 weeks (difference
of 8%, p = 0.038) (Figure 3B; individual subject responses
in Additional file 1: Figure S3). As an alternative ap-
proach, we dichotomized based upon the natural separ-
ation in the three-gene-mean suggested by Figure 1
(Th2-high defined as baseline three-gene-mean > 0.5).
With this alternate threshold, the mean change in FEV1
was significantly higher in Th2-high asthma subjects at
2 weeks (difference of 10%, p = 0.006) and 4 weeks
(difference of 13%, p = 0.0001), with a similar trend at 8
weeks (difference of 8%, p = 0.055).
To evaluate the sensitivity and specificity of the three-
gene-mean for prediction of ICS response, we performed






























































Figure 2 Relationship of baseline three-gene-mean to other markers of Th2 airway inflammation and ICS response. Three-gene-mean
values were measured from airway epithelial brushings acquired at bronchoscopy before and after 8 weeks of ICS. Covariates were also measured
before and after ICS, and log-transformed to yield normally distributed values prior to statistical calculations. Scatterplots of covariates (on a log10
scale) vs three-gene-mean are shown with least-squares linear regression lines before (black) and after (gray) ICS for the following variables: A.
Exhaled nitric oxide (FeNO), r = 0.75, p = 0.00023 off ICS; r = 0.53, p = 0.024 on ICS. B. Blood eosinophils, r = 0.58, p = 0.003; r = 0.40, p = 0.071 on ICS.
C. Total serum IgE, r = 0.33, p = 0.11 off ICS; r = 0.42, p = 0.067 on ICS. D. PC20 to methacholine, r = -0.65, p = 0.0006 off ICS; PC20 not obtained after
ICS treatment.
Bhakta et al. Clinical and Translational Allergy 2013, 3:24 Page 5 of 9
http://www.ctajournal.com/content/3/1/24as an increase of ≥12% and ≥200 ml, paralleling ATS
recommendations [18]. Six out of 22 asthma subjects
had a positive response to ICS at 8 weeks (7 out of 23 at
4 weeks). The area under the curve (AUC) of baseline
three-gene-mean for prediction of FEV1 response was
0.87 at 8 weeks (Figure 4A) and 0.94 at 4 weeks
(Additional file 1: Figure S4A). Validation in the second-
ary cohort (4 responders out of 15 subjects at 8 weeks)
confirmed a high AUC for three-gene-mean with a value
of 0.91 at 8 weeks (Figure 4B) and 0.77 at 4 weeks






















Figure 3 Relationship between FEV1 changes in response to ICS and
pre-bronchodilator FEV1 is relative to week 0 (baseline). A. Percent change
circles) weeks, versus Th2 airway inflammation measured by the three-gene
B. Mean percent change in FEV1 stratified by a dichotomous Th2 grouping
0.1, as suggested by the midline between the peaks for subjects with asthm
and Th2-high subjects respectively. Error bars are standard error of the meaquantitative performance of the three-gene-mean by
ROC analysis.
Given our aim to create a gold-standard of Th2 airway
inflammation with the three-gene-mean, we next com-
pared this metric's performance to that of classical mark-
ers of allergic inflammation and AHR, which as shown
above and summarized in Additional file 1: Table S2, were
well correlated with the three-gene-mean with the ex-
ception of total serum IgE. Although our datasets are
underpowered to perform a multivariate comparison as
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baseline Th2 airway inflammation in asthma. Percent change in
in FEV1 at 2 (gray solid circles), 4 (black solid circles) and 8 (open
-mean at baseline, and associated least-squares linear regression lines.
, with Th2-high defined as a three-gene-mean greater than a value of
a not on ICS in Figure 1. Dotted and solid lines represent Th2-low














































Figure 4 Predictive performance of three-gene-mean and other markers of Th2 inflammation for 8 week ICS response. Receiver
operating characteristic (ROC) curves were made to assess the ability of the three-gene-mean and other markers to predict an improvement in
FEV1 after 8 weeks of ICS. Improvement in FEV1 was defined as an increase of at least 200 ml and 12% relative to week 0. A. ROC curves for
baseline measurements of the three-gene-mean (labeled “TGM”), FeNO, blood eosinophils, total serum IgE, and PC20 to methacholine in the
primary cohort. Six out of 22 subjects had an improvement in FEV1. B. ROC curves for the secondary cohort to validate the findings in panel A.
Four out of 15 subjects had an improvement in FEV1. In both panels, the line of unity is represented by a dashed gray line, corresponding to an
AUC of 0.5.
Table 2 Summary of ROC analysis for three-gene-mean
Primary cohort Secondary cohort
4 weeks 8 weeks 4 weeks 8 weeks
AUC 0.94 0.87 0.77 0.91
Sensitivity (%)
three-gene-mean threshold*
0.1 100 100 100 100
0.5 100 100 100 100
0.57 100 100 75 100
Specificity (%)
three-gene-mean threshold*
0.1 56 50 33 27
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three-gene-mean at 8 weeks was greater than the AUC
for FeNO, blood eosinophils and IgE (Figure 4A). In
addition, although AHR is not considered a Th2-specific
characteristic per se, measurement of AHR by metha-
choline challenge has been shown to be a valuable guide
in adjustment of ICS dosing as compared to a standard
guideline-based algorithm in a prior study [19]. We
found that the AUC for prediction of ICS-response was
better for the three-gene-mean than for PC20 methacho-
line (Figure 4A). Validation in the secondary cohort
(4 responders out of 15 subjects at 8 weeks) showed that
the three-gene-mean again had a higher AUC compared
to other potential biomarkers of ICS response (Figure 4B
at 8 weeks; Additional file 1: Figure S4B at 4 weeks).
Finally, whereas an individual gene component may
have a higher AUC than the three-gene-mean in some in-
stances, the three-gene-mean has more consistent per-
formance across the datasets (Additional file 1: Table S3).
This consistency in the three-gene-mean led us to exam-
ine whether the mean of the three markers with which
it was best correlated with—blood eosinophils, FeNO,
and PC20—may also perform well in predicting ICS re-
sponse. The results in Additional file 1: Table S3 show
AUC's for this combined non-invasive metric that are
comparable to, albeit lower than those for the three-
gene-mean.0.5 69 63 42 36
0.57 81 75 42 45
* For the baseline three-gene-mean thresholds, the cutoff of 0.5 is suggested
by the two peaks in Figure 1, the cutoff of 0.1 is derived from the mean + 2SD
of the healthy distribution, and the cutoff of 0.57 maximizes the sum of
sensitivity and specificity of the three-gene-mean in the primary cohort at
8 weeks.Th2 inflammation and symptom improvement with ICS
Using a baseline three-gene-mean cutoff value of 0.1,
subjects with Th2-low asthma did not have significantly
different baseline percentage of days with symptoms(defined as any shortness of breath, chest tightness,
wheeze, cough, or sputum) compared to those with
Th2-high asthma (82% for Th2-high, 78% for Th2-low,
p = 0.7). However, subjects with Th2-high asthma did
have a significantly greater improvement in the percent-
age of days with symptoms compared to Th2-low
asthma subjects after 4 weeks of ICS (mean absolute de-
crease of 42% vs 10%, p = 0.03), and a trend at 8 weeks
(mean absolute decrease of 53% vs 24%, p = 0.08). With-
out an accepted threshold to dichotomize the response
in symptoms, we did not perform ROC analyses to com-
pare predictors.
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This qPCR-based three-gene-mean metric contributes to
our understanding of Th2 inflammation in asthma by: 1)
demonstrating that previously published epithelial gene
expression markers correlate well with FeNO, 2) identi-
fying a strong association between Th2 inflammation
and smooth muscle dysfunction (measured by AHR)
among patients with asthma, and 3) demonstrating that
epithelial gene expression markers have good predictive
capacity for both lung function and symptomatic im-
provement with ICS. Since it is obtained through bron-
choscopic evaluation, the major application of this three-
gene-mean metric of Th2 inflammation will be in clinical
and translational research studies. However, development
of a quantitative and reproducible gold-standard for clin-
ical research applications is a necessary pre-requisite for
the assessment of non-invasive biomarkers.
This qPCR-based metric has several advantages over
our prior classification which used hierarchical cluster-
ing of microarray data. Most notably, microarrays and
hierarchical clustering cannot be repeated in a standard-
ized way in future studies. This new metric of Th2 air-
way inflammation requires as little as 20 ng of RNA
from airway epithelial cells using qPCR, a widely avail-
able technique. With the use of inter-run calibrators,
three-gene-mean values can be compared across differ-
ent studies, platforms, reagents, and laboratories [20].
Finally, a continuous measurement of Th2 airway in-
flammation provides more statistical power to detect as-
sociations with other clinical and molecular features of
asthma, without losing the ability to apply a threshold to
make dichotomous Th2-high vs low classifications for
practical applications. An important finding from appli-
cation of this continuous metric is that regardless of
where the threshold is made, Th2-low asthma subjects
have low rather than absent Th2 inflammation. Analysis
of microarray-based gene expression in airway biopsies
from our earlier study also showed that a continuum of
Th2 inflammation is present even among those with
Th2-low inflammation [10].
To place our metric into context, we correlated the
three-gene-mean with a range of other markers of Th2
inflammation and ICS responsiveness. We found a
strong correlation between the three-gene-mean and
blood eosinophils, FeNO, and PC20 methacholine, but
not with total serum IgE. In particular, FeNO was well
correlated with the three-gene-mean both before and
after a course of ICS, suggesting that FeNO measure-
ments are a good surrogate for the three-gene-mean. Ni-
tric oxide production is increased in the lungs of asthma
patients in part due to increased transcription of the
NOS2 gene encoding inducible nitric oxide synthase in
epithelial cells [21]. We have previously found airway
epithelial expression of periostin, CLCA1, and serpinB2to be correlated with NOS2 expression [10,22]. However,
we have not previously directly compared our epithelial
expression markers to FeNO. FeNO's reported ability to
identify a subgroup of severe asthmatics on high-dose
ICS that selectively respond to the Th2-targeted, anti-
interleukin-13 monoclonal antibody lebrikizumab, also
supports its strength as a Th2 marker [22,23]. Notably,
however, FeNO has not performed well in clinical stud-
ies as a measure by which to modulate ICS dose, which
may be from poor reproducibility and other technical is-
sues [22,24]. Therefore, the identification of additional
non-invasive markers of Th2 inflammation may be valu-
able. Sputum eosinophils have also been proposed as a
marker of Th2 airway inflammation, with studies show-
ing that modulating ICS therapy by sputum eosinophils
counts can lead to a reduced number and severity of ex-
acerbations [24,25]. Unfortunately, we did not have spu-
tum eosinophil counts in the present study, but certainly
its relationship to the three-gene-mean will be of interest
in future studies.
Importantly, sputum eosinophil measurements are dif-
ficult to perform in clinical practice; an easier alternative
is protein levels of serum periostin, which like FeNO,
identified a subgroup of severe asthmatics responsive to
lebrikizumab [22,23]. Although serum periostin was not
measured in the current study, future studies that relate
the three-gene-mean to serum periostin will potentially
help optimize the threshold for serum periostin that best
identifies individuals that will respond to ICS or Th2-
targeted therapies. Such an analysis will also provide a
better understanding of the relationship between serum
periostin and Th2 airway inflammation, especially in the
setting of other, non-asthma epithelial disorders that can
potentially alter serum periostin levels such as allergic dis-
eases of the gastrointestinal tract, skin, and upper airway.
Using ROC curves, we compared the performance of
the three-gene-mean to other markers of Th2 inflamma-
tion in predicting response to treatment with ICS. The
more consistent performance for the three-gene-mean
across our two datasets compared to its components
supports the concept that the mean may be resistant to
individual gene-level variation that is less reflective of
Th2-driven inflammation. The three-gene-mean had a
larger AUC than FeNO, eosinophils, total serum IgE,
PC20, and a combination of three non-invasive measures
(FeNO, eosinophils, and PC20) for FEV1 improvement.
Overall, this comparative performance analysis suggests
that non-invasive measures can accurately predict ICS re-
sponse, and that the three-gene-mean is a valid research
tool by which to establish a lung-based gold-standard for
evaluating other biomarkers of Th2 inflammation.
Airway epithelial cells are increasingly recognized as a
source of key initiators of allergic inflammation includ-
ing IL-33, IL-25, and TSLP [26]. Therefore, it is possible
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useful biomarkers of allergic inflammation. Although we
did not measure the expression levels of these genes by
qPCR in this study to test this particular hypothesis,
genome-wide microarray expression profiling on the co-
horts in this study shows no difference between subjects
with asthma and healthy controls for IL-33, IL-25, and
TSLP (data not shown). Whether these negative results
are due to limitations of the probes on the microarray or
true lack of transcript-level differences can be addressed
in a future study.
As an alternative to biomarkers, published reports
have identified lung function measures as predictors of
steroid response in asthma. Baseline values for FEV1 as
percent of predicted, the FEV1/FVC ratio, and broncho-
dilator percent reversibility were strongly correlated with
improvement in FEV1 in response to ICS [6,7]. All three
of these spirometry-based predictors use baseline FEV1,
which is a parameter used in the calculation of the out-
come, improvement in FEV1. Therefore, the predictive
value of these lung function measures for lung function
improvement is in part tautological. In addition, biological
markers have the advantage over lung function measures
that these markers can identify the presence of specific in-
flammatory pathways targeted by specific therapeutics.
The most salient examples would be Th2-targeted bio-
logics such as mepolizumab and lebrikizumab.
Th2 sub-grouping of asthma has broad clinical re-
search applications. The presence of features of asthma
despite low levels of Th2 inflammation raises the ques-
tion of whether other underlying abnormalities are
present in the airways of patients with Th2-low asthma.
Hypotheses proposed for the pathology in Th2-low
asthma include intrinsic airway smooth muscle dysfunc-
tion and non-Th2 inflammatory pathways such as Th17-
driven inflammation [27,28]. The ability to characterize
a patient with asthma as Th2-low and study airway spec-
imens from this subgroup enables testing of these pro-
posed underlying abnormalities. It is likely that some
individuals with Th2-high asthma also have non-Th2
pathways of inflammation active given that Th2 status
only partially explains asthmatic features such as airway
mucin stores and AHR [9]. Assignment of Th2 status to
research subjects will also allow the study of abnormal-
ities that co-exist with Th2 inflammation.
We recognize a number of limitations in the current
study. The sample size did not prevent validation of the
three-gene-mean's predictive capacity, but it did prevent
us from making statistical comparisons of predictive
capacity amongst competing markers of Th2 inflamma-
tion via logistic regression because of the risk of over-
fitting the model. Although 8 weeks of ICS treatment
may be considered a relatively short timeframe, a num-
ber of detailed studies of the effects of ICS on FEV1 haveshown that there is minimal additional response beyond
3-6 weeks [6,7]. Furthermore, reductions in exacerba-
tions and symptoms are likely more relevant to patients
and their health-care providers than improvements in
FEV1. Nevertheless, it was previously shown that a short-
term, 6 week improvement in FEV1 to ICS was significantly
associated with reductions in exacerbations and symptoms
over a longer term of 4 months [7]. Ongoing and future
longitudinal studies will better establish the performance
of the three-gene-mean in predicting longer-term asthma
control and exacerbation frequency. Our study also is lim-
ited to young adults with mild-to-moderate asthma. The
performance of the three-gene-mean in a wider age range,
and in patients with severe asthma on high doses of ICS
requires further study.Conclusions
In summary, we have described a qPCR-based assay of
Th2 airway inflammation using RNA derived from epi-
thelial brushings, which we term the three-gene-mean.
This three-gene-mean contributes to our understanding
of disease mechanisms by identifying Th2 inflammation
as significantly associated with AHR in human asthma.
By measuring this three-gene-mean and FeNO concur-
rently we show that they are highly correlated, linking
our bronchoscopically obtained measure to a non-
invasively obtained biomarker. Finally, we show that the
three-gene-mean predicts ICS-response, both in terms
of lung function and in patient-oriented measures such
as symptoms, yielding ROC curve performance that
equals or exceeds that of a set of non-invasive measures.
Based on these features, we propose the three-gene
-mean as a quantitative standard for measurement of
Th2 inflammation in human asthma when epithelial
brushings can be obtained. This tool can be applied in
clinical research studies for the study of disease mecha-
nisms and assessment of non-invasive biomarkers.Additional file
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